PharmaRelations appoints new CDO and EVP Denmark
Niels Buch Leander has been appointed new Chief Digital Officer (CDO) and Executive Vice President (EVP) Denmark.
As CDO, he will lead PharmaRelations’ digital agenda and drive the company’s transformation toward data-driven, intelligent, and scalable solutions for clients across the Nordics. His responsibility as EVP Denmark will include strengthening local operations, expanding client offerings, and leading the continued growth of the Danish business.
“We are thrilled to welcome Niels to PharmaRelations,” says Åsa Uppströmer, CEO, PharmaRelations “His deep understanding of digitalization and the evolving needs of the life science industry makes him an invaluable addition to our leadership team. His experience will further strengthen our ability to support clients with future-ready solutions while accelerating our growth ambitions in the Nordic market.”
The appointment of Niels Buch Leander marks an important milestone in strengthening the company’s digital capabilities and expanding its footprint in Denmark, states PharmaRelations.
Niels Buch Leander
With over 20 years of experience in digital transformation and data strategy across the life science industry, Niels Buch Leander brings a unique combination of strategic vision and operational excellence to the organization, describes PharmaRelations.
He has extensive experience in transforming business digitally, building high performing teams, and integrating technologies such as AI, automation and data analytics into regulated environments. His background spans several senior leadership roles within NNIT and Eraneos with focus on strategy, technology, and consulting.
“I am excited to join PharmaRelations at such an important time for the company and the industry,” says Niels Buch Leander. “Life science is rapidly evolving, and digitalization is now a fundamental driver of innovation, quality, and competitiveness. I look forward to contributing to PharmaRelations’ mission of enabling excellence for clients across the Nordics and strengthening our position as a leading life science consulting partner.”
Published: December 9, 2025

